Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res. 1991:3–11.

Crespin A, Le Bescop C, de Gunzburg J, Vitry F, Zalcman G, Cervesi J, Bandinelli PA. A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Front Oncol. 2023;13:1075593.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116–26.

Article  CAS  PubMed  Google Scholar 

Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 2002;169:5538–45.

Article  CAS  PubMed  Google Scholar 

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P. A new member of the immunoglobulin superfamily-CTLA-4. Nature. 1987;328:267–70.

Article  CAS  PubMed  Google Scholar 

O’Melia MJ, Manspeaker MP, Thomas SN. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC. Cancer Immunol Immunother. 2021;70:2179–95.

Article  PubMed  PubMed Central  Google Scholar 

Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen YJ, Chitre AS, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020;579:274–8.

Article  CAS  PubMed  Google Scholar 

Innominato PF, Karaboué A, Bouchahda M, Bjarnason GA, Lévi FA. The future of precise cancer chronotherapeutics. Lancet Oncol. 2022;23:e242.

Article  CAS  PubMed  Google Scholar 

Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, Molina-Pinelo S, Bernabé-Caro R. Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy. Cancers (Basel). 2020;12:3729.

Karaboué A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, et al. Time-dependent efficacy of checkpoint inhibitor nivolumab: results from a pilot study in patients with metastatic non-small-cell lung cancer. Cancers (Basel). 2022;14:896.

Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22:1777–86.

Article  CAS  PubMed  Google Scholar 

Karaboué A, Bisseux L, Pavese I, Collon T. Circadian variation in nivolumab efficacy in patients with advanced non-small cell lung cancer. J Clin Oncol. 2020;38:e21585–e21585.

Article  Google Scholar 

Lévi F, Focan C, Karaboué A, de la Valette V, Focan-Henrard D, Baron B, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 2007;59:1015–35.

Article  PubMed  Google Scholar 

Lévi F, Giacchetti S, Adam R, Zidani R, Metzger G, Misset JL. Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Eur J Cancer. 1995;31a:1264–70.

Article  PubMed  Google Scholar 

Lévi F, Giacchetti S, Zidani R, Brezault-Bonnet C, Tigaud JM, Goldwasser F, Misset JL. Chronotherapy of colorectal cancer metastases. Hepatogastroenterology. 2001;48:320–2.

PubMed  Google Scholar 

Cortellini A, Barrichello A, Alessi JV, Ricciuti B, Vatz V, Newsom-Davis T, et al. 512 Time-of-day of pembrolizumab infusion and clinical outcomes of patients with NSCLC: too soon to promote morning infusions. J Immunother Cancer. 2022;10:A536–A537.

Google Scholar 

Rousseau A, Tagliamento M, Auclin E, Aldea M, Frelaut M, Levy A, et al. Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Eur J Cancer. 2023;182:107–14.

Article  CAS  PubMed  Google Scholar 

Vilalta A, Arasanz H, Rodriguez-Remirez M, Lopez I, Puyalto A, Lecumberri A, et al. 967P The time of anti-PD-1 infusion improves survival outcomes by fasting conditions simulation in non-small cell lung cancer. Ann Oncol. 2021;32:S835.

Article  Google Scholar 

Collon T, Innominato P, Chouahnia K, Adam R, Levi F. Improved survival on morning pembrolizumab with or without chemotherapy during initial treatment for stage IV non-small cell lung cancer. J Clin Oncol. 2023;41:e21055–e21055.

Article  Google Scholar 

Catozzi S, Assaad S, Delrieu L, Favier B, Dumas E, Hamy AS, et al. Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study. Eur J Cancer. 2024;199:113571.

Article  CAS  PubMed  Google Scholar 

Chen R, Hou X, Yang L, Zhao D. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: a systematic review and meta-analysis. Thorac Cancer. 2019;10:607–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeung C, Kartolo A, Tong J, Hopman W & Baetz T. Association of circadian timing of initial infusions of immune checkpoint inhibitors with survival in advanced melanoma. Immunotherapy. https://doi.org/10.2217/imt-2022-0139 (2023).

Gonçalves L, Gonçalves D, Esteban-Casanelles T, Barroso T, Soares de Pinho I, Lopes-Brás R, et al. Immunotherapy around the clock: impact of infusion timing on stage IV melanoma outcomes. Cells. 2023;12:2068.

Ortego I, Molina-Cerrillo J, Pinto A, Santoni M, Alonso-Gordoa T, Lopez Criado MP, et al. Time-of-day infusion of immunotherapy in metastatic urothelial cancer (mUC): Should it be considered to improve survival outcomes? J Clin Oncol. 2022;40:e16541–e16541.

Article  Google Scholar 

Patel JS, Woo Y, Draper A, Jansen CS, Carlisle JW, Innominato PF, et al. 848 Impact of immunotherapy time-of-day infusion on overall survival in patients with metastatic renal cell carcinoma. J Immunother Cancer. 2022;10:A886–A886.

Google Scholar 

Fernandez-Mañas L, Gonzalez Aguado L, Aversa C, Ferrer-Mileo L, Garcia de Herreros M, Jiménez N, et al. Does the time-of-day administration of immune checkpoint inhibitors affect efficacy in patients with metastatic renal cell carcinoma? A single-center study. J Clin Oncol. 2023;41:681–681.

Article  Google Scholar 

Dizman N, Govindarajan A, Zengin ZB, Meza LA, Tripathi N, Sayegh N, et al. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2023;41:678–678.

Article  Google Scholar 

Nomura M, Hosokai T, Tamaoki M, Yokoyama A, Matsumoto S, Muto M et al. Timing of the infusion of nivolumab for patients with recurrent or metastatic squamous cell carcinoma of the esophagus influences its efficacy. Esophagus, 1–10 https://doi.org/10.1007/s10388-023-01006-y (2023).

Ishizuka Y, Narita Y, Sakakida T, Wakabayashi M, Kodama H, Honda K, et al. Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer. J Clin Oncol. 2024;42:268–268.

Article  Google Scholar 

Pascale A, Allard MA, Benamar A, Levi F, Adam R, Rosmorduc O. Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2024;42:457–457.

Article  Google Scholar 

Landre T, Karaboue A, Buchwald ZS, Innominato P, Qian DC, Assie J, et al. Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: a meta-analysis. J Clin Oncol. 2023;41:2562–2562.

Article  Google Scholar 

van Rensburg HJJ, Liu ZA, Abdul Razak AR, Spreafico A, Bedard PL, Hansen AR, et al. The effect of circadian rhythm on clinical outcome in patients receiving pembrolizumab in the INSPIRE pan-cancer trial. J Clin Oncol. 2022;40:2589–2589.

Article  Google Scholar 

Czeisler CA, Gooley JJ. Sleep and circadian rhythms in humans. Cold Spring Harb Symp Quant Biol. 2007;72:579–97.

Article  CAS  PubMed  Google Scholar 

Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–49.

Article  CAS  PubMed  Google Scholar 

Doherty CJ, Kay SA. Circadian control of global gene expression patterns. Annu Rev Genet. 2010;44:419–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Innominato PF, Lévi FA, Bjarnason GA. Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev. 2010;62:979–1001.

Article  CAS  PubMed  Google Scholar 

Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharm Toxicol. 2010;50:377–421.

Article  Google Scholar 

Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci. 2012;35:445–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lévi F, Canon C, Dipalma M, Florentin I, Misset JL. When should the immune clock be reset? From circadian pharmacodynamics to temporally optimized drug delivery. Ann NY Acad Sci. 1991;618:312–29.

Article  PubMed  Google Scholar 

Scheiermann C, Gibbs J, Ince L, Loudon A. Clocking in to immunity. Nat Rev Immunol. 2018;18:423–37.

Article  CAS  PubMed  Google Scholar 

Reddy AB, O’Neill JS. Healthy clocks, healthy body, healthy mind. Trends Cell Biol. 2010;20:36–44.

Article  PubMed  PubMed Central  Google Scholar 

Shibata S, Tahara Y, Hirao A. The adjustment and manipulation of biological rhythms by light, nutrition, and abused drugs. Adv Drug Deliv Rev. 2010;62:918–27.

Article  CAS  PubMed  Google Scholar 

Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharm Toxicol. 2007;47:593–628.

Article  CAS